6-K
Definium Therapeutics, Inc. (DFTX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2021
Commission File Number: 001-40360
MIND MEDICINE (MINDMED) INC.
(Name of registrant)
1055 West Hastings Street, Suite 1700
Vancouver, British Columbia
V6E 2E9
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
| ¨ Form 20-F | x Form 40-F |
|---|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MIND MEDICINE (MINDMED) INC. | |||
|---|---|---|---|
| (Registrant) | |||
| Date: December 16, 2021 | By: | /s/ Robert Barrow | |
| Name: | Robert Barrow | ||
| Title: | Chief Executive Officer |
Form 6-K Exhibit Index
| Exhibit Number | Document Description |
|---|---|
| 99.1 | Material Change Report dated December 16, 2021. |
Exhibit 99.1
Form 51-102F3
Material Change Report
| Item 1 | Name and Address of Company |
|---|
Mind Medicine (MindMed) Inc. (the “Company”)
1055 West Hastings Street, Suite 1700
Vancouver, British Columbia
V6E 2E9
| Item 2 | Date of Material Change |
|---|
December 13, 2021
| Item 3 | News Release |
|---|
On December 14, 2021, a news release was disseminated through the newswire services of GlobalNewswire and subsequently filed on SEDAR at www.sedar.com.
| Item 4 | Summary of Material Change |
|---|
On December 13, 2021, the Company appointed (i) Robert Barrow as Chief Executive Officer and a director of the Company, (ii) Carol Vallone as Chair of the board of directors, (iii) Andreas Krebs as Vice Chair of the board of directors, and Perry Dellelce has ceased to be a director and Chair of the board of directors.
| Item 5 | Full Description of Material Change |
|---|---|
| 5.1 | Full Description of Material Change |
| --- | --- |
On December 13, 2021, the Company appointed (i) Robert Barrow as Chief Executive Officer and a director of the Company, (ii) Carol Vallone as Chair of the board of directors, (iii) Andreas Krebs as Vice Chair of the board of directors, and Perry Dellelce has ceased to be a director and Chair of the board of directors.
| 5.2 | Disclosure for Restructuring Transactions |
|---|
Not Applicable.
| Item 6 | Reliance on subsection 7.1(2) of National Instrument 51-102 |
|---|
Not Applicable.
| Item 7 | Omitted Information |
|---|
Not Applicable.
| Item 8 | Executive Officer |
|---|
For further information, please contact Rob Barrow, Chief Executive Officer of the Company, at 212-220-6633.
| Item 9 | Date of Report |
|---|
December 16, 2021.